Top Markets
#1 MowCat MowCat +49.01%
#2 Derive Derive +22.98%
#3 Audiera Audiera +21.36%
#4 Velvet Velvet +19.74%
#5 Biconomy Biconomy +17.74%
#6 Geodnet Geodnet +16.44%
#7 aPriori aPriori +13.80%
#8 Quack AI Quack AI +13.49%
#9 Cross Cross +13.44%
#10 Humanity Humanity +11.22%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Tetra Bio-Pharma Inc. Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc.

TBP
Rank in Stocks #35576
Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical... Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
Share Price
$0.01851783
Last synced: 2023-05-23
Market Cap
$3.71M
Change (1 day)
-0.04%
Change (1 year)
0.00%
Country
CA
Trade Tetra Bio-Pharma Inc. (TBP)

Category

Healthcare
P/E ratio for Tetra Bio-Pharma Inc. (TBP)
P/E ratio as of 2026 TTM: 0
According to Tetra Bio-Pharma Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Tetra Bio-Pharma Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.